Viking Therapeutics, Inc. (VKTX) Stock
Key stats
- Market cap
- $3.63B
- Price / Earnings ratio
- -5.8x
- EPS (TTM)
- -$5.41
- Volume
- Loading
- 52-week high
- $43.15
- 52-week low
- $23.82
Source: third-party data provider, as of November 13, 2026
Compare with VKTX
Recent news

UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
VKTX

VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
VKTX

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
VKTX

VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses
VKTX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 52.64
- MACD 12/26/9
- -0.30
- EMA 9 of MACD
- -0.85
- MACD histogram
- 0.55
- SMA 50
- $29.54
- Price below SMA 50
- EMA 50
- $29.00
- Price below EMA 50
- SMA 200
- $32.19
- Price below SMA 200
- EMA 200
- $31.86
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$1.03 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
VKTX

VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
VKTX

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
VKTX

VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses
VKTX

VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress
VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress
VKTX

Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
VKTX

Viking Therapeutics Q3 Earnings Call Highlights
Viking Therapeutics Q3 Earnings Call Highlights
VKTX

VKTX Stock Slides Overnight After Q3 Loss: CEO’s Obesity Drug Launch Timeline Frustrates Retail
VKTX Stock Slides Overnight After Q3 Loss: CEO’s Obesity Drug Launch Timeline Frustrates Retail
VKTX

Should You Buy Viking Therapeutics Stock Ahead of Q3 Results?
Should You Buy Viking Therapeutics Stock Ahead of Q3 Results?
VKTX

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28
Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28
VKTX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Viking Therapeutics, Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Brian Lian Ph.D. | President, CEO & Director | 1966 |
| Mr. Gregory S. Zante CPA | Chief Financial Officer | 1971 |
| Mr. Michael Morneau | Vice President of Finance & Administration | 1965 |
| Ms. Katherine Mercier | Vice President of Quality & Compliance | — |
| Mr. Kenneth J. Herman M.B.A. | Senior Vice President of Commercial, Marketing & Sales | — |
| Dr. Geoffrey E. Barker Ph.D. | Chief Development Officer | — |
| Dr. Nils U. Olsson Ph.D. | Senior Vice President of Technical Operations | — |
| Dr. Hubert C. Chen M.D., M.P.H. | Chief Medical Officer | 1969 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 52.64
- MACD 12/26/9
- -0.30
- EMA 9 of MACD
- -0.85
- MACD histogram
- 0.55
- SMA 50
- $29.54
- Price below SMA 50
- EMA 50
- $29.00
- Price below EMA 50
- SMA 200
- $32.19
- Price below SMA 200
- EMA 200
- $31.86
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $94.00
- Average
- $106.00
- High
- $118.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -11.6 | -8.4 | ||||||||||
| 2022 | -24.0 | -12.5 | -8.5 | -24.0 | -12.3 | +35.7 | +6.7 | +10.8 | -15.8 | +50.7 | -7.3 | +127.6 |
| 2023 | +2.8 | +25.1 | +46.2 | +21.3 | -0.7 | -26.2 | -6.1 | -2.5 | -23.7 | -9.8 | +27.7 | +43.0 |
| 2024 | +32.1 | +221.7 | -3.8 | +0.1 | -18.5 | -14.9 | +3.0 | +17.3 | +8.4 | +17.0 | -27.4 | -21.9 |
| 2025 | -20.4 | -8.4 | -6.0 | +20.7 | -6.4 | +1.5 | +22.1 | -17.2 | -4.4 | +39.1 | +2.3 | +1.8 |
| 2026 | -18.0 | +13.1 | -2.4 | -5.4 | +9.1 | +24.8 | -15.3 | +0.5 | -3.2 | -10.6 | +6.0 |



